Ad
BTX - Brooklyn ImmunoTherapeutics Stock Trading
About | Brooklyn ImmunoTherapeutics Inc. (NYSE:BTX)
None
Quote | Brooklyn ImmunoTherapeutics Inc. (NYSE:BTX)
| Last: | $9.01 |
|---|---|
| Change Percent: | -6.34% |
| Open: | $9.59 |
| Close: | $9.01 |
| High: | $9.6 |
| Low: | $8.7 |
| Volume: | 880,740 |
| Last Trade Date Time: | 10/22/2021 04:57:58 pm |
News | Brooklyn ImmunoTherapeutics Inc. (NYSE:BTX)
-
Brooklyn ImmunoTherapeutics ( NASDAQ: BTX ) said on Tuesday that it was changing its name to Eterna Therapeutics Inc. to reflect its focus on developing therapies using its patented in-licensed mRNA cell engineering technologies. The name change will be effec...
-
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s...
Message Board Posts | Brooklyn ImmunoTherapeutics Inc. (NYSE:BTX)
| Subject | By | Source | When |
|---|---|---|---|
| No posts yet. | |||
News, Short Squeeze, Breakout and More Instantly...
Brooklyn ImmunoTherapeutics Inc. Company Name:
BTX Stock Symbol:
NYSE Market:
Brooklyn ImmunoTherapeutics Inc. Website:
Ad
-
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s...
-
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnos...
-
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today ann...